Samina Hamied, 48, third generation heir to Cipla, founded in 1935 by her grandfather Khwaja Abdul Hamied, challenges herself ...

Ethris and Lonza collaborate to develop spray-dried mRNA vaccines for respiratory disease prevention: Munich, Germany Wednesday, April 9, 2025, 13:00 Hrs [IST] Ethris, a clinical- ...

Ethris has partnered with contract development and manufacturing organisation Lonza for the development of room-temperature ...

MUNICH, Germany & BASEL, Switzerland I April 07, 2025 I Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and Lonza, one of the world’s largest ...

Ethris, a clinical-stage biotechnology company creating RNA therapeutics and vaccines, and Lonza entered a collaboration to develop room-temperature stable, spray-dried formulations of mRNA-based ...

TCTM Kids IT Education Inc. ("TCTM" or the "Company"), a leading provider of IT-focused supplementary STEM education services in China, today announced that it has entered into share purchase ...

Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and Lonza, one of the world's largest contract development and manufacturing organizations ...

Under the terms of the agreement, Lonza will provide spray-drying and particle engineering for vaccine candidates based on Ethris’ stabilized non-immunogenic mRNA (SNIM® RNA) and stabilized ...

Ethris and Lonza agreed to collaborate on the development of room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates, designed for mucosal delivery to combat respiratory ...

German biotech Ethris, a company developing RNA therapeutics and vaccines, and Swiss contract development and manufacturing organization Lonza (SWX: LONN), have announced a collaboration. The deal is ...